Unknown

Dataset Information

0

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.


ABSTRACT: Recombinant immunotoxins (RIT) are chimeric proteins containing an Fv that binds to tumor cells, fused to a fragment of Pseudomonas exotoxin (PE) that kills the cell. Their efficacy is limited by their short half-life in the circulation. Chemical modification with polyethylene glycol (PEG) is a well-established method to extend the half-lives of biologics. Our goal was to engineer RITs with an increase in half-life and high cytotoxic activity. We introduced single cysteines at different locations in five anti-mesothelin RITs and employed site-specific PEGylation to conjugate them to 20-kDa PEG. Because our previous PEGylation method using ?-mercaptoethanol reduction gave poor yields of PEG-modified protein, we employed a new method using tris(2-carboxyethyl)phosphine to reduce the protein and could PEGylate RITs at approximately 90% efficiency. The new proteins retained 19% to 65% of cytotoxic activity. Although all proteins are modified with the same PEG, the radius of hydration varies from 5.2 to 7.1, showing PEG location has a large effect on protein shape. The RIT with the smallest radius of hydration has the highest cytotoxic activity. The PEGylated RITs have a 10- to 30-fold increase in half-life that is related to the increase in hydrodynamic size. Biodistribution experiments indicate that the long half-life is due to delayed uptake by the kidney. Antitumor experiments show that several PEG-RITs are much more active than unmodified RIT, and the PEG location greatly affects antitumor activity. We conclude that PEGylation is a useful approach to improve the half-life and antitumor activity of RITs.

SUBMITTER: Zheng Z 

PROVIDER: S-EPMC7056543 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.

Zheng Zeliang Z   Okada Ryuhei R   Kobayashi Hisataka H   Nagaya Tadanobu T   Wei Junxia J   Zhou Qi Q   Lee Fred F   Bera Tapan K TK   Gao Yun Y   Kuhlman William W   Tai Chin-Hsien CH   Pastan Ira I  

Molecular cancer therapeutics 20191223 3


Recombinant immunotoxins (RIT) are chimeric proteins containing an Fv that binds to tumor cells, fused to a fragment of <i>Pseudomonas</i> exotoxin (PE) that kills the cell. Their efficacy is limited by their short half-life in the circulation. Chemical modification with polyethylene glycol (PEG) is a well-established method to extend the half-lives of biologics. Our goal was to engineer RITs with an increase in half-life and high cytotoxic activity. We introduced single cysteines at different l  ...[more]

Similar Datasets

| S-EPMC4936933 | biostudies-literature
| S-EPMC5899471 | biostudies-literature
| S-EPMC4372481 | biostudies-literature
| S-EPMC5789939 | biostudies-literature
| S-EPMC3166498 | biostudies-literature
| S-EPMC8317202 | biostudies-literature
| S-EPMC3024457 | biostudies-literature
| S-EPMC7424708 | biostudies-literature
| S-EPMC3715784 | biostudies-literature
| S-EPMC3940292 | biostudies-literature